Stock Events

Stock Events

Galmed Pharmaceuticals 

$3.88
28
-$0.04-1.02% 20:00 Today
+$0.14+3.61%20:02After hours

Statistics

Day High
4.23
Day Low
3.88
52W High
13.2
52W Low
3.29
Volume
4,082
Avg. Volume
101,105
Mkt Cap
4.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25NovExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Next
Next
-3.12
-2.19
-1.26
-0.33
Expected EPS
-3.12
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLMD. It's not an investment recommendation.
Alphabet
4
GOOGL
AMD
4
AMD
Apple
3
AAPL
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap3.75B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap1.99B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
Show more...
CEO
Allen Baharaff
Employees
6
Country
Israel
ISIN
IL0011313900
WKN
000A1XFUX

Listings

STU
DE
GPH.STU
F
DE
GPH.F
XNAS
US
GLMD
BOATS
BOATS
GLMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Galmed Pharmaceuticals stock price today?▼
The current price of GLMD is $3.88 USD — it has decreased by -1.02% in the past 24 hours. Watch Galmed Pharmaceuticals stock price performance more closely on the chart.
What is Galmed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Galmed Pharmaceuticals stocks are traded under the ticker GLMD.
Is Galmed Pharmaceuticals stock price growing?▼
GLMD stock has fallen by -6.84% compared to the previous week, the month change is a +574.78% rise, over the last year Galmed Pharmaceuticals has showed a +203.13% increase.
What is Galmed Pharmaceuticals market cap?▼
Today Galmed Pharmaceuticals has the market capitalization of 4.04M
When is the next Galmed Pharmaceuticals earnings date?▼
Galmed Pharmaceuticals is going to release the next earnings report on November 25, 2026.
What is Galmed Pharmaceuticals revenue for the last year?▼
Galmed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Galmed Pharmaceuticals net income for the last year?▼
GLMD net income for the last year is -10.31M USD.
How many employees does Galmed Pharmaceuticals have?▼
As of September 04, 2026, the company has 6 employees.
In which sector is Galmed Pharmaceuticals located?▼
Galmed Pharmaceuticals operates in the Health & Wellness sector.
When did Galmed Pharmaceuticals complete a stock split?▼
The last stock split for Galmed Pharmaceuticals was on August 19, 2026 with a ratio of 1:8.
Where is Galmed Pharmaceuticals headquartered?▼
Galmed Pharmaceuticals is headquartered in Ramat Gan, Israel.